Kamari Pharma

Company Overview

Snapshot

Founded in October 2018, Kamari Pharma operates with 1–10 employees. The company has raised $31 million across 3 funding rounds from 4 investors. In June 2025, Kamari Pharma announced the closing of a $23 million financing round.

Business overview

Kamari Pharma is a biopharmaceutical company focused on developing and commercializing proprietary small molecule inhibitors of TRPV3. This cation channel, primarily expressed in keratinocytes, is a target for treating various dermatological conditions with unmet medical needs, including keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, and Drugs Discovery & Development.

Strategic signal

In April 2026, Kamari Pharma initiated clinical trials for its skin disease drug, coinciding with a company name change. This move signals a significant advancement from research and development into the clinical stage, indicating progress towards commercialization and validating its therapeutic approach for dermatological conditions.

Company Intelligence Q&A

What was Kamari Pharma's most recent funding round?

In June 2025, Kamari Pharma announced the closing of a $23 million financing round to advance its first-in-class oral TRPV3 inhibitor for rare genetic skin diseases. This round saw participation from investors including Pontifax and BRM Group.

When did Kamari Pharma begin clinical trials for its skin disease drug?

In April 2026, Kamari Pharma began clinical trials for its skin disease drug, an event that coincided with the company changing its name.

What was Kamari Pharma's funding activity in September 2022?

In September 2022, Kamari Pharma secured funding from the Guangzhou Sino-Israel Biotech Investment Fund (GIBF).

What is Kamari Pharma's primary focus in drug development?

Kamari Pharma is focused on developing and commercializing proprietary small molecule inhibitors of TRPV3, a cation channel involved in various dermatological conditions.

Which investors participated in Kamari Pharma's January 2020 funding round?

In January 2020, Kamari Pharma received funding from investors including.